Product Program year 2024 Source: CMS Open Payments

Evobrutinib

Open in the dashboard

General payments

$631,172

141 payments

Research payments

$0

0 payments

Through program year 2024, $631,172 in general payments and $0 in research payments were reported against Evobrutinib.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2024 General $3,139 6
2023 General $628,034 135

Breakdown

Who paid General payments · program years 2023–2024
  1. EMD Serono, Inc. $575,615 112 payments
  2. Ares Trading SA $30,650 19 payments
  3. Merck KGaA $24,908 10 payments
Top recipients General payments · program year 2024
  1. Riley Bove Internal Medicine · San Francisco, CA $2,250 72% · 1 payment
  2. Timothy West Neurology · Salt Lake City, UT $660 21% · 1 payment
  3. Miguel Paz Soldan Neurology · Rochester, MN $91 3% · 1 payment
  4. Yang Mao Draayer Neurology · Farmington Hills, MI $71 2% · 1 payment
  5. Mohamed Sadiq Neurology · Layton, UT $33 1% · 1 payment

The top 5 of 6 recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Internal Medicine $2,250 72% · 1 practitioner
  2. Neurology Psychiatry & Neurology $889 28% · 5 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2024
  1. California $2,250 72% · 1 recipient
  2. Utah $727 23% · 3 recipients
  3. Minnesota $91 3% · 1 recipient
  4. Michigan $71 2% · 1 recipient

Each share is of general payments naming this product in 2024 where a state was reported.

141 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record